Skip to main content
Erschienen in: Osteoporosis International 4/2014

01.04.2014 | Case Report

Nonuremic calciphylaxis precipitated by teriparatide [rhPTH(1–34)] therapy in the setting of chronic warfarin and glucocorticoid treatment

verfasst von: E. K. Spanakis, D. E. Sellmeyer

Erschienen in: Osteoporosis International | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Calciphylaxis occurs rarely in the absence of end stage renal disease. Predisposing factors for nonuremic calciphylaxis (NUC) include hyperparathyroidism, coagulopathies, connective tissue disease, liver disease, glucocorticoid use, and malignancy. Warfarin can facilitate vascular calcification by reducing vitamin K-dependent carboxylation of matrix-Gla proteins. An 86-year-old Caucasian woman with a history of polymyalgia rheumatica, two spontaneous deep venous thromboses (DVTs) and multiple fractures was treated with calcium, vitamin D, prednisone, and warfarin. The patient's low bone density was treated initially with estrogen, then oral bisphosphonate, which was discontinued due to upper gastrointestinal symptoms. Nasal calcitonin was initiated. After 10 years of calcitonin treatment, she was changed to teriparatide. Two months after initiating teriparatide, she developed lower extremity edema and painful erythematous nodular lesions on her calves bilaterally, that progressed to necrotic ulcers despite antibiotic therapy. Biopsy of the lesions showed calcification in the media of small blood vessels and subcutaneous fat with fat necrosis, consistent with calciphylaxis. Teriparatide was discontinued. Aggressive wound care, antibiotics, and intravenous zoledronic acid were initiated. With cessation of teriparatide therapy and intensive wound care, the patient's lesions resolved over 8 months. We report the first case of NUC precipitated by teriparatide therapy. Our patient had multiple underlying predisposing factors including a connective tissue disorder, glucocorticoid therapy, warfarin use, and possible underlying coagulopathy given her history of multiple DVTs. In such patients, alternative osteoporosis therapies may be preferred.
Literatur
1.
Zurück zum Zitat Nigwekar SU, Wolf M, Sterns RH, Hix JK (2008) Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc of Nephrol: CJASN 3:1139–1143CrossRef Nigwekar SU, Wolf M, Sterns RH, Hix JK (2008) Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc of Nephrol: CJASN 3:1139–1143CrossRef
2.
Zurück zum Zitat Bryant JHWW (1898) A case of calcification of the arteries and obliterative endarteritis associated with hydronephrosis in a child aged six months. Guy's Hosp Rep 55:17–20 Bryant JHWW (1898) A case of calcification of the arteries and obliterative endarteritis associated with hydronephrosis in a child aged six months. Guy's Hosp Rep 55:17–20
3.
Zurück zum Zitat Selye H, Gabbiani G, Strebel R (1962) Sensitization to calciphylaxis by endogenous parathyroid hormone. Endocrinology 71:554–558PubMedCrossRef Selye H, Gabbiani G, Strebel R (1962) Sensitization to calciphylaxis by endogenous parathyroid hormone. Endocrinology 71:554–558PubMedCrossRef
4.
Zurück zum Zitat Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRef Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRef
5.
Zurück zum Zitat Angelis M, Wong LL, Myers SA, Wong LM (1997) Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery 122:1083–1089, discussion 1089–1090PubMedCrossRef Angelis M, Wong LL, Myers SA, Wong LM (1997) Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery 122:1083–1089, discussion 1089–1090PubMedCrossRef
6.
Zurück zum Zitat Budisavljevic MN, Cheek D, Ploth DW (1996) Calciphylaxis in chronic renal failure. J Am Soc Nephrol: JASN 7:978–982PubMed Budisavljevic MN, Cheek D, Ploth DW (1996) Calciphylaxis in chronic renal failure. J Am Soc Nephrol: JASN 7:978–982PubMed
7.
Zurück zum Zitat Weenig RH (2008) Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kappa-B. J Am Acad Dermatol 58:458–471PubMedCrossRef Weenig RH (2008) Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kappa-B. J Am Acad Dermatol 58:458–471PubMedCrossRef
8.
Zurück zum Zitat Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR (2007) Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 56:569–579PubMedCrossRef Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR (2007) Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 56:569–579PubMedCrossRef
9.
Zurück zum Zitat Rogers NM, Teubner DJ, Coates PT (2007) Calcific uremic arteriolopathy: advances in pathogenesis and treatment. Semin Dialysis 20:150–157CrossRef Rogers NM, Teubner DJ, Coates PT (2007) Calcific uremic arteriolopathy: advances in pathogenesis and treatment. Semin Dialysis 20:150–157CrossRef
10.
Zurück zum Zitat Vedvyas C, Winterfield LS, Vleugels RA (2012) Calciphylaxis: a systematic review of existing and emerging therapies. J Am Acad Dermatol 67:e253–e260PubMedCrossRef Vedvyas C, Winterfield LS, Vleugels RA (2012) Calciphylaxis: a systematic review of existing and emerging therapies. J Am Acad Dermatol 67:e253–e260PubMedCrossRef
11.
Zurück zum Zitat Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE (2001) Catabolic effects of continuous human PTH (1–38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142:4047–4054PubMed Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE (2001) Catabolic effects of continuous human PTH (1–38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142:4047–4054PubMed
12.
Zurück zum Zitat Asobie N, Wong E, Cook MG (2008) Calciphylaxis in a diabetic patient provoked by warfarin therapy. Clin Exp Dermatol 33:342–344PubMedCrossRef Asobie N, Wong E, Cook MG (2008) Calciphylaxis in a diabetic patient provoked by warfarin therapy. Clin Exp Dermatol 33:342–344PubMedCrossRef
13.
Zurück zum Zitat Wallin R, Cain D, Sane DC (1999) Matrix Gla protein synthesis and gamma-carboxylation in the aortic vessel wall and proliferating vascular smooth muscle cells—a cell system which resembles the system in bone cells. Thromb Haemost 82:1764–1767PubMed Wallin R, Cain D, Sane DC (1999) Matrix Gla protein synthesis and gamma-carboxylation in the aortic vessel wall and proliferating vascular smooth muscle cells—a cell system which resembles the system in bone cells. Thromb Haemost 82:1764–1767PubMed
15.
Zurück zum Zitat Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W (2003) The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Investig 112:357–366PubMedCentralPubMedCrossRef Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W (2003) The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Investig 112:357–366PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G (1997) Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386:78–81PubMedCrossRef Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G (1997) Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386:78–81PubMedCrossRef
17.
Zurück zum Zitat Vedvyas C, Winterfield LS, Vleugels RA (2011) Calciphylaxis: a systematic review of existing and emerging therapies. J Am Acad Dermatol 67(6):e253–e260PubMedCrossRef Vedvyas C, Winterfield LS, Vleugels RA (2011) Calciphylaxis: a systematic review of existing and emerging therapies. J Am Acad Dermatol 67(6):e253–e260PubMedCrossRef
18.
Zurück zum Zitat Fine A, Zacharias J (2002) Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 61:2210–2217PubMedCrossRef Fine A, Zacharias J (2002) Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 61:2210–2217PubMedCrossRef
19.
Zurück zum Zitat Mohammed IA, Sekar V, Bubtana AJ, Mitra S, Hutchison AJ (2008) Proximal calciphylaxis treated with calcimimetic 'Cinacalcet'. Nephrol Dial Transplant 23:387–389PubMedCrossRef Mohammed IA, Sekar V, Bubtana AJ, Mitra S, Hutchison AJ (2008) Proximal calciphylaxis treated with calcimimetic 'Cinacalcet'. Nephrol Dial Transplant 23:387–389PubMedCrossRef
20.
Zurück zum Zitat Kang AS, McCarthy JT, Rowland C, Farley DR, van Heerden JA (2000) Is calciphylaxis best treated surgically or medically? Surgery 128:967–971, discussion 971–962PubMedCrossRef Kang AS, McCarthy JT, Rowland C, Farley DR, van Heerden JA (2000) Is calciphylaxis best treated surgically or medically? Surgery 128:967–971, discussion 971–962PubMedCrossRef
21.
Zurück zum Zitat Cecchini MG, Felix R, Fleisch H, Cooper PH (1987) Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. J Bone Miner Res: Off J Am Soc Bone Miner Res 2:135–142CrossRef Cecchini MG, Felix R, Fleisch H, Cooper PH (1987) Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. J Bone Miner Res: Off J Am Soc Bone Miner Res 2:135–142CrossRef
22.
Zurück zum Zitat Schliep S, Schuler G, Kiesewetter F (2008) Successful treatment of calciphylaxis with pamidronate. Eur J Dermatol: EJD 18:554–556PubMed Schliep S, Schuler G, Kiesewetter F (2008) Successful treatment of calciphylaxis with pamidronate. Eur J Dermatol: EJD 18:554–556PubMed
Metadaten
Titel
Nonuremic calciphylaxis precipitated by teriparatide [rhPTH(1–34)] therapy in the setting of chronic warfarin and glucocorticoid treatment
verfasst von
E. K. Spanakis
D. E. Sellmeyer
Publikationsdatum
01.04.2014
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 4/2014
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-013-2580-6

Weitere Artikel der Ausgabe 4/2014

Osteoporosis International 4/2014 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.